3,108 Shares in United Therapeutics Corporation (NASDAQ:UTHR) Purchased by GSA Capital Partners LLP

Key Points

• GSA Capital Partners LLP has acquired 3,108 shares of United Therapeutics Corporation, valued at approximately $958,000, indicating increasing institutional interest in the biotechnology company.
• Insider trading activity includes CFO James Edgemond selling 12,000 shares for approximately $3.9 million, while Director Richard Giltner sold 3,036 shares for about $879,000, suggesting notable changes in insider positions.
• Despite a recent earnings miss with an EPS of $6.41 against a consensus estimate of $6.80, analysts maintain a generally positive outlook, with a consensus rating of "Moderate Buy" and an average price target of $379.69 for the stock.

GSA Capital Partners LLP bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 3,108 shares of the biotechnology company's stock, valued at approximately $958,000.

Other hedge funds also recently modified their holdings of the company. FMR LLC lifted its holdings in United Therapeutics by 36.5% in the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after buying an additional 393,777 shares during the period. Vaughan Nelson Investment Management L.P. acquired a new position in shares of United Therapeutics in the 1st quarter valued at $101,354,000. GAMMA Investing LLC lifted its stake in shares of United Therapeutics by 29,415.2% in the 1st quarter. GAMMA Investing LLC now owns 221,954 shares of the biotechnology company's stock valued at $68,422,000 after purchasing an additional 221,202 shares during the period. Northern Trust Corp boosted its position in shares of United Therapeutics by 29.1% in the 4th quarter. Northern Trust Corp now owns 488,854 shares of the biotechnology company's stock worth $172,487,000 after purchasing an additional 110,298 shares during the last quarter. Finally, AustralianSuper Pty Ltd grew its stake in shares of United Therapeutics by 49.0% during the first quarter. AustralianSuper Pty Ltd now owns 282,739 shares of the biotechnology company's stock worth $87,160,000 after purchasing an additional 92,959 shares during the period. Institutional investors own 94.08% of the company's stock.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 12,000 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the completion of the transaction, the chief financial officer directly owned 8,118 shares in the company, valued at $2,641,353.66. This represents a 59.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the sale, the director directly owned 19,384 shares in the company, valued at approximately $5,613,606.40. This represents a 13.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 70,681 shares of company stock valued at $21,318,359 over the last quarter. 10.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on UTHR. Cantor Fitzgerald initiated coverage on United Therapeutics in a report on Monday, June 2nd. They set an "overweight" rating and a $405.00 target price on the stock. HC Wainwright set a $400.00 price objective on shares of United Therapeutics and gave the company a "buy" rating in a report on Thursday. UBS Group lowered their target price on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research note on Monday, June 30th. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a research report on Tuesday, July 8th. Finally, Bank of America lowered their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a research report on Wednesday, June 11th. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $379.69.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $274.70 on Friday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $417.82. The stock's 50 day moving average price is $298.39 and its two-hundred day moving average price is $314.07. The stock has a market capitalization of $12.39 billion, a price-to-earnings ratio of 10.72, a PEG ratio of 6.15 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The business had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same quarter last year, the business earned $5.85 earnings per share. United Therapeutics's revenue for the quarter was up 11.7% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.